{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:30Z","timestamp":1793805930797,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.017","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:25:11Z","timestamp":1783682711000},"page":"484-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-7203","authenticated-orcid":false,"given":"Daniel J.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furaha","family":"Kariburyo-Yay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himani","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon G.","family":"Tepsick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinelo","family":"Orji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer R.","family":"Ghate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.06.017_bib0001","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5489\/cuaj.10167","article-title":"Guidelines for the management of castrate-resistant prostate cancer","volume":"4","author":"Saad","year":"2010","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0002","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139440","article-title":"Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model","volume":"10","author":"Scher","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0004","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0005","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0006","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0007","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0008","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V.1.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 22, 2025. NCCN.org."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0009","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2024.0851","article-title":"Genetic testing in men with metastatic castration-resistant prostate cancer","volume":"10","author":"Barata","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0010","doi-asserted-by":"crossref","first-page":"99-","DOI":"10.1200\/JCO.2023.41.6_suppl.99","article-title":"Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US)","volume":"41","author":"Barata","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0011","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2217\/fon-2021-1113","article-title":"Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan","volume":"18","author":"Leith","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0012","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.2217\/fon-2021-0153","article-title":"Real-world genetic testing patterns in metastatic castration-resistant prostate cancer","volume":"17","author":"Shore","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0013","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.2024.42.4_suppl.210","article-title":"Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Shore","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0014","doi-asserted-by":"crossref","first-page":"8147","DOI":"10.1158\/1078-0432.CCR-04-1402","article-title":"Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer","volume":"10","author":"Dagher","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0015","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0016","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41416-019-0611-6","article-title":"Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort","volume":"121","author":"Rouyer","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0017","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MOU.0b013e32835e2253","article-title":"Castrate-resistant prostate cancer: postdocetaxel management","volume":"23","author":"Zhao","year":"2013","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0018","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0019","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.732599","article-title":"Efficacy and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Wei","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0021","unstructured":"National Cancer Institute. Radium-223 improves survival in patients with advanced prostate cancer. 2013. Available at:https:\/\/www.cancer.gov\/types\/prostate\/research\/radium-223-improves-survival. Accessed October 4, 2024."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0022","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. 2020. Available at:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate. Accessed October 4, 2024."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0023","unstructured":"US Food & Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer. 2022. Available at:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer. Accessed October 25, 2024."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0024","unstructured":"US Food & Drug Administration. FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. 2025. Available at:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication. Accessed April 27, 2026."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0025","unstructured":"ClinicalTrials.gov. An international prospective open-label, randomized, phase III study comparing 177Lu-PSMA-617 in combination with standard of care (SoC), versus SoC alone, in adult male patients with metastatic hormone sensitive prostate cancer (mHSPC) (PSMAddition). 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04720157. Accessed April 27, 2026."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0026","unstructured":"US Food & Drug Administration. FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer. 2023. Available at:https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration. Accessed October 25, 2024."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0027","unstructured":"US Food & Drug Administration. FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer. 2023. Available at:https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate. Accessed October 25, 2024."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0028","unstructured":"US Food & Drug Administration. FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer. 2023. Available at:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca-mutated-metastatic-castration. Accessed October 25, 2024."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0029","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0031","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0032","unstructured":"Friends of Cancer Research. Considerations for use of real-world evidence in oncology. Available at:https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Use_of_Real-World_Evidence_in_Oncology_0.pdf. Accessed February 19, 2026."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0033","article-title":"Improving real-world mortality data quality in oncology research: augmenting electronic medical records with obituary, social security death index, and commercial claims data","volume":"7","author":"Shao","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2024.10.3581","article-title":"RWD23 addition of open administrative claims significantly improves capture of mortality in electronic health record (EHR)-focused real-world data (RWD)","volume":"27","author":"Slipski","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.urolonc.2026.06.017_bib0035","unstructured":"US Food & Drug Administration. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. 2020. Available at:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer. Accessed October 4, 2024."},{"key":"10.1016\/j.urolonc.2026.06.017_bib0036","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-020-00720-2","article-title":"Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry","volume":"15","author":"Chowdhury","year":"2020","journal-title":"Target Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:27:38Z","timestamp":1793802458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005752"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}